GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers

Inclusion Criteria: * Histologically-proven diagnosis of advanced (AJCC, 7th Edition: stage III or IV) or aggressive solid organ cancer. * Patients must provide written consent for a core needle biopsy sample of tumor tissue (primary or metastatic). * Have evidence of measurable disease (according to RECIST Version 1.1: http:// www.recist.com). * Have an ECOG Performance Score of 0 to 2. * Have a life expectancy of at least 3 months. * Have adequate organ and marrow function * Negative serum pregnancy test for females of childbearing potential. * Have negative test result for HIV and Hepatitis B or C testing. * Have baseline anti-vaccinia antibody titer \< 10. Exclusion Criteria: * Current or anticipated use of other investigational agents or marketed anticancer agent while on study (from the time of enrollment through the time of surgery). * Patients who have received chemotherapy or radiotherapy within 4 weeks prior to entering the study. * Small pox vaccination for 4 weeks before study therapy and during study treatment. * Have received prior gene therapy or therapy with cytolytic virus of any type. * Have clinically significant cardiac disease * Oxygen saturation \<90% measured by pulse oximetry at rest. * Receiving concurrent antiviral agent active against vaccinia virus (e.g., cidofovir, vaccinia immunoglobulin, imatinib, ST-246) during the course of study. * Have known allergy to ovalbumin or other egg products. * Have clinically significant dermatological disorders (e.g., eczema, psoriasis, or any unhealed skin wounds or ulcers) * Have a history of allergy to iodinated contrast media. * Patients with known brain metastases * Pregnant or nursing